SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,218,624.4003947. The last known price of Ethereum is 1,739.90377069 USD and is down -9.84 over the last 24 hours. It is currently trading on 14359 active market(s) with $18,820,901,710.98 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is caught in a broad crypto selloff alongside Bitcoin, with traders pointing to forced liquidations and wider risk-off pressure. The community is split between calling the drop capitulation and buying the dip, and warning that weak demand could lead to further losses.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 0.92173784 USD and is down -8.73 over the last 24 hours. It is currently trading on 1896 active market(s) with $4,059,642,828.82 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

A broad crypto selloff, with Bitcoin weakness weighing on XRP, dominates discussion. Traders are divided between treating the steep decline as a buying opportunity and fearing further losses, with bearish posts also questioning XRPs supply and utility.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,752,062,860.16806072. The last known price of Dogecoin is 0.05689686 USD and is down -11.89 over the last 24 hours. It is currently trading on 1545 active market(s) with $1,128,721,930.78 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention amid a sharp, extended selloff that traders link to weakness across the broader crypto market, with concern about fresh lows and limited buying interest. The community is split between holders viewing the decline as a buying opportunity and skeptics expecting further losses and questioning the coins utility.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 637,554,569.48929238 with 591,573,607.37721086 in circulation. The last known price of Solana is 69.50906472 USD and is down -10.60 over the last 24 hours. It is currently trading on 1189 active market(s) with $4,775,978,662.51 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is under pressure amid a broad crypto selloff, with traders focused on its sharp decline and whether further losses or a bottom may be ahead. Bearish posts warn of a continuing downtrend, while others view the weakness as a buying opportunity and are accumulating or staking SOL.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins sharp decline is weighing on Strategy as traders treat it as a leveraged Bitcoin proxy; discussion also points to its announced removal from MSCI indices as a potential source of forced selling. Sentiment is largely bearish, with concerns about dilution and financing alongside some dip-buying and hopes for a Bitcoin rebound.

Avalanche (AVAX) is a cryptocurrency launched in 2020. Avalanche has a current supply of 471,438,169.1160568 with 446,436,169.1160568 in circulation. The last known price of Avalanche is 6.99518175 USD and is down -15.00 over the last 24 hours. It is currently trading on 1135 active market(s) with $402,139,637.32 traded over the last 24 hours. More information can be found at https://avax.network/.

Avalanche

A sharp AVAX selloff amid Bitcoin weakness and a broader altcoin rout is dominating discussion. Traders are split between viewing the drop as a buying opportunity and warning of further losses, while many complain that rebounds keep fading.

Litecoin (LTC) is a cryptocurrency . Users are able to generate LTC through the process of mining. Litecoin has a current supply of 84,000,000 with 77,830,936.34364598 in circulation. The last known price of Litecoin is 43.58319249 USD and is down -11.87 over the last 24 hours. It is currently trading on 1567 active market(s) with $330,181,316.06 traded over the last 24 hours. More information can be found at https://litecoin.org/.

Litecoin

Litecoin is drawing attention for a sharp selloff amid broader crypto weakness, with traders saying it has underperformed and lost support. Bearish posts warn of further downside, while others view the decline as a buying opportunity and are accumulating.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

Analyst downgrades and price-target cuts following UiPaths investor-day presentations have fueled a sharp selloff, with traders debating whether concerns about slowing growth and AI monetization outweigh the companys agentic-automation opportunity. Bulls view the decline as a valuation opportunity, while bears question whether new products and partnerships can translate into stronger business growth.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingos Q3 results, accelerating user growth and higher full-year guidance have driven a sharp rally. Bulls point to stronger engagement and the possibility of short covering, while skeptics focus on the EPS miss and lingering concerns about monetization, valuation and AI competition.

Quant (QNT) is a cryptocurrency and operates on the Ethereum platform. Quant has a current supply of 14,881,364 with 12,072,738 in circulation. The last known price of Quant is 141.66985362 USD and is down -11.02 over the last 24 hours. It is currently trading on 416 active market(s) with $104,643,915.79 traded over the last 24 hours. More information can be found at https://quant.network/.

Quant

QNT is drawing attention amid a sharp pullback and broader crypto-market weakness, with traders debating whether selling has further to run or the decline is a chance to accumulate. Long-term bulls point to Quants anticipated role in banking tokenization and a planned Clearing House network launch, while skeptics question how soon that thesis will translate into token demand.

statis crypto Watchlist

Bitcoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HeartFlow (HTFL) Reports Q3 Loss, Beats Revenue Estimates

HeartFlow (HTFL) delivered earnings and revenue surprises of +70.00% and +11.92%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026

IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026 IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026PR NewswireCAESAREA, Israel, Nov. 11, 2026 CAESAREA, Israel, Nov. 11, 2026 /PRNewswire/ -- IceCure...

IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio

IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP PortfolioPR NewswireCAESAREA, Israel, November 9, 2026 Newly Granted Patent Adds to IceCure's...

Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates

Natera (NTRA) delivered earnings and revenue surprises of -129.41% and +13.04%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer CryoablationPR NewswireCAESAREA, Israel, Oct. 27, 2026 First...

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. Sites

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. Sites IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense Breast Cancer Cryoablation at Two U.S. SitesPR NewswireCAESAREA, Israel, Oct. 20, 2026 CAESAREA, Israel, Oct. 20...

IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense Breast Cancer Cryoablation at EUSOBI 2026

IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense Breast Cancer Cryoablation at EUSOBI 2026 IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense Breast Cancer Cryoablation at EUSOBI 2026PR NewswireCAESAREA, Israel, October 13, 2026Scientific...

IceCure Expands ProSense ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site

IceCure Expands ProSense ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site IceCure Expands ProSense ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical SitePR NewswireCAESAREA, Israel, Oct. 6, 2026CAESAREA...

IceCure Secures China NMPA Approval for ProSense Cryoablation System

ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.

IceCure Medical Receives Regulatory Approval to Market ProSense in China

IceCure Medical Receives Regulatory Approval to Market ProSense in China IceCure Medical Receives Regulatory Approval to Market ProSense in China PR Newswire CAESAREA, Israel, Sept. 10, 2026 CAESAREA, Israel, Sept. 10, 2026 /PRNewswire/ --IceCure Medical Ltd.(NASDAQ: ICCM) ("IceCure," "IceCure...

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.

Icecure Medical Ltd

Bullish Sentiment

<ul class="summary-bullets"><li>ProSense was granted FDA marketing authorization in October 2025.</li><li>The CEO hinted that the firm sees further commercial opportunities for the system.&nbsp;</li><li>According to data from Koyfin, all three analysts covering ICCM rate it ‘Buy’ or higher.</li></ul>Shares of IceCure Medical Ltd. (ICCM) exploded over 200% on Wednesday, fueled by positive news of accelerating adoption of the company’s ProSense system in the U.S.IceCure reported a 70% increase in its active U.S. commercial install base of ProSense systems used for breast cancer treatment since the FDA granted marketing authorization in October 2025.The stock is now on track for its best day since August 2021, if gains hold.<h2 class="st-heading-2">ICCM Execs Weigh In</h2>IceCure said it continues to add new ProSense systems at clinics and hospitals across the country. The systems are already being used for procedures in major cities, including Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix, Memphis and many other communities.“With growing physician interest, expanding clinical acceptance, and increased patient awareness, we believe we remain in the early stages of a significant commercial opportunity for breast cancer cryoablation in the U.S. We are focused on continuing to expand our installed base, supporting physicians with training and education and increasing access to ProSense for eligible patients,” IceCure CEO Eyal Shamir said.<h2 class="st-heading-2">What Is ProSense?</h2>ProSense is a minimally invasive system that destroys tumors by freezing them with liquid nitrogen. It offers an alternative to traditional surgery for removing tumors, often with faster recovery, less pain, and fewer complications. Procedures can typically be done in an office setting.IceCure’s ProSense system is currently the first and only medical device specifically authorized by the FDA for the local treatment of low-risk breast cancer in women aged 70 and older, combined with standard hormone therapy, including patients who may not be suitable for surgery.<h2 class="st-heading-2">How Did ICCM Retail Traders React?</h2>On Stocktwits, retail sentiment toward ICCM stock surged from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume climbed from ‘normal’ to ‘extremely high.’A Stocktwits user said that they see way more upside for the stock.<stembedurl>https://www.stocktwits.com/VlaDracula/message/6567163374</stembedurl>Another termed the stock an incredible investment opportunity.<stembedurl>https://www.stocktwits.com/Veghead12/message/656716302</stembedurl>According to data from Koyfin, all three analysts covering ICCM rate it ‘Buy’ or higher. The stock has an average price target of $44.50, representing a potential upside of nearly 2000% from the stock's last closing price.<a href="https://stocktwits.com/symbol/ICCM">ICCM stock</a> has lost about 67% this year after reporting persistent first-quarter losses.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/arqq-stock-on-track-for-a-four-month-high-what-s-driving-the-rally-june-17-2026/cZKKRz7R7IC">ARQQ Stock On Track For A Four-Month High – What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ICCM Stock On Track For Best Day In Nearly 5 Years — What’s Driving The 200% Rally?

IceCure reported a 70% increase in its active U.S. commercial install base of ProSense systems. 

Equity

IceCure reported a 70% increase in its active U.S. commercial install base of ProSense systems. 


Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.73
Prev Close	$0.7005
Open	$0.6833
Dividend Yield	0.00%
50-Day Moving Average	$1.35
Beta	0.88
Avg. Volume	163,329.01
PE Ratio	-0.11

52-Week High	$22.50
52-Week Low	$0.65
Market Capitalization	$2.5M
EPS (Annual)	-$7.10
Price to Book	0.21
Revenue Per Employee	$48,971.01

Feed

News

Sentiment

Earnings

Fundamentals

Info

ICCM Fundamentals